NCT02473666

Brief Summary

Study the influence of transfusion related Patient Blood Management Program actions on transfusion-related outcome measures and cost.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
3.4 years until next milestone

First Submitted

Initial submission to the registry

May 11, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 16, 2015

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2019

Completed
Last Updated

November 12, 2020

Status Verified

November 1, 2020

Enrollment Period

7.9 years

First QC Date

May 11, 2015

Last Update Submit

November 10, 2020

Conditions

Hemorrhage

Keywords

Patient Blood ManagementRed Blood CellsPlatelet

Outcome Measures

Primary Outcomes (1)

  • Percentage of transfusions per participant

    Participant wich had transfusion will be identified and the administrative, financial and clinical data will be compared to participants without transfusions

    participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years

Secondary Outcomes (3)

  • Percentage of transfusion of any blood product per participant

    participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years

  • Cost of any blood product per participant

    participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years

  • Survey of Patient Blood Management System

    participants will be followed form date of hospital entry until date of discharge or date of death up to 3 years

Study Arms (1)

All Health Conditions.

All Health Conditions. Area of Focus: Transfusions of blood products.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All cases of all in hospital patients. Area of Focus: Transfusions of blood products.

You may qualify if:

  • Only case records, all discharged patients of the University Hospital of Zürich

You may not qualify if:

  • Not discharged from our Hospital.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Zurich

Zurich, 8091, Switzerland

Location

MeSH Terms

Conditions

Hemorrhage

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Donat R Spahn, Prof

    IFA University Hospital Zurich

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2015

First Posted

June 16, 2015

Study Start

January 1, 2012

Primary Completion

December 1, 2019

Study Completion

December 1, 2019

Last Updated

November 12, 2020

Record last verified: 2020-11

Locations

CH(1)